11 reports

  • CSTI-100 - DRUG PROFILE

The study included positive control sibutramine (## mg/ kg once daily, ##. ## percent weight loss), a serotonin and noradrenaline reuptake inhibitor, which is currently marketed for the treatment of obesity.

  • Hormone
  • Obesity
  • Therapy
  • World
  • Product Initiative
  • Melanin-Concentrating Hormone Receptor 1 (G-

The study included positive control sibutramine (## mg/ kg once daily, ##. ##% weight loss), a serotonin and noradrenaline reuptake inhibitor, which is currently marketed for the treatment of obesity.

  • Hormone
  • Obesity
  • Therapy
  • Vaccine
  • United States
  • Preferred Drugs List, as at August 2016
  • Health Services
  • Healthcare
  • Hospital
  • Ireland
  • Product Development Milestones

DEC ##, 2016: " CYMBALTA CAPSULES ##MG ## MG" (SEROTONIN-NORADRENALINE REUPTAKE INHIBITOR) APPROVED FOR AN ADDITIONAL INDICATION OF PAIN ASSOCIATED WITH OSTEOARTHRITIS Shionogi & Co., Ltd and Eli Lilly Japan K. K. announced that " CYMBALTA Capsules

  • Chronic Disease
  • Chronic Pain
  • Pain Relief
  • Pathology
  • Pharmaceutical
  • Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) II-92
  • Therapy
  • Europe
  • United States
  • World
  • Selective Serotonin Reuptake Inhibitors Sales and
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Antidepressant
  • Hormone
  • Therapy
  • China
  • Demand
  • MAJOR DEPRESSIVE DISORDER - GLOBAL DRUG FORECAST AND MARKET ASSESSMENT TO 2025

ANTIDEPRESSANT EFFICACY AND TOLERABILITY OF MILNACIPRAN, A DUAL SEROTONIN and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.

  • Antidepressant
  • Depression
  • Therapy
  • Allergan plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Selective Serotonin Reuptake Inhibitors Sales and
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Antidepressant
  • Pharmaceutical
  • Therapy
  • China
  • Demand
  • Jan 09, 2017: Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain
  • FEATURED NEWS & PRESS RELEASES
  • Analgesic
  • Musculoskeletal Disorder
  • Opioid
  • Pharmaceutical
  • Therapy
  • CSTI-100 - DRUG PROFILE

THE STUDY INCLUDED POSITIVE CONTROL SIBUTRAMINE (## MG/ KG ONCE DAILY, ##. ## PERCENT WEIGHT LOSS), A SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR, WHICH IS CURRENTLY MARKETED FOR THE TREATMENT OF OBESITY.

  • Digestive System Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • United States
  • GLAXOSMITHKLINE PLC - DISCONTINUED PIPELINE PRODUCTS

The serotonin-noradrenaline reuptake inhibitors (SNRIs) are a class of drug that inhibit reuptake of both serotonin and noradrenaline.

  • Infectious Disease
  • Pathology
  • Therapy
  • Vaccine
  • GlaxoSmithKline plc